Address Translational & Commercial Challenges to Seamlessly Utilize Liquid Biopsy Technologies to Drive Smarter, Accelerated Oncology Drug Development
The 10th Liquid Biopsy for Precision Oncology Summit is the leading annual meeting for pharma, biotech, diagnostics, consortia, academia and patient voices to accelerate collaboration and progress in the rapidly advancing field of liquid biopsy.Â
Now in its 10th year, this meeting delivers unparalleled insights, data, technology updates, and strategies spanning the entire drug development pipeline - from preclinical discovery, through clinical translation, to regulatory approval, reimbursement, and commercial adoption.Â
If you are working in precision oncology, or need enhanced insights into your patient population, optimized diagnostic and prognostic tools, or earlier detection of disease, this meeting should be considered a staple entry in your conference calendar. Across ctDNA, MRD, multi-omic biomarkers, and novel analytes, you will see how pharma are strategically integrating liquid biopsies into therapeutic pipelines, how diagnostic companies are designing more sensitive assays, and how the field is overcoming barriers to widespread clinical adoption.Â
What’s more?
Tickets are complimentary* for biopharma.
Attending Companies Include








